Evidence map›Paper›PMID 33866988›Full record

ArticleEpidemiology and infection2021

COVID-19 re-infection in Shahroud, Iran: a follow-up study.

Fariba Zare, Maryam Teimouri, Ahmad Khosravi, Marzieh Rohani-Rasaf, Reza Chaman, Ali Hosseinzadeh, Hozhabr Jamali Atergeleh, Ehsan Binesh, Mohammad Hassan Emamian

Abstract read
In one paragraph

Article in Epidemiology and infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fariba ZareCenter for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahroud, Iran.ORCID 0000-0002-7326-1151
Maryam TeimouriDepartment of Biochemistry, School of Allied Medical Sciences, Shahroud University of Medical Sciences, Shahroud, Iran.
Ahmad KhosraviDepartment of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran.ORCID 0000-0002-1106-3782
Marzieh Rohani-RasafDepartment of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran.ORCID 0000-0002-7945-7542
Reza ChamanDepartment of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran.
Ali HosseinzadehDepartment of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran.ORCID 0000-0002-0055-9408
Hozhabr Jamali AtergelehDepartment of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran.
Ehsan BineshClinical Research Development Unit, Imam Hossein Hospital, Shahroud University of Medical Sciences, Shahroud, Iran.
Mohammad Hassan EmamianOphthalmic Epidemiology Research Center, Shahroud University of Medical Sciences, Shahroud, Iran.ORCID 0000-0002-1994-1105

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although many people became infected and recovered during the COVID-19 epidemic, the immunity duration and re-infection in recovered patients have recently attracted many researchers. The aim of this study was to evaluate the recurrence of the infection in recovered individuals over a 9-month period after the onset of the COVID-19 epidemic. In this study, data related to COVID-19 patients in Shahroud city were collected using the electronic system for registering suspicious patients and also by checking patients' hospital records. In this study, from 20 March 2020 to 20 November 2020 (9 months), a total of 8734 suspected patients with respiratory symptoms were observed and followed up. RT-PCR was positive for 4039 patients. During this period, out of the total number of positive cases of COVID-19, 10 cases became re-infected after complete recovery. The risk of re-infection was 2.5 per thousand (0.95 CI 1.2-4.5). The mean time interval between the first infection and re-infection was 134.4 ± 64.5 days (range 41-234 days). The risk of re-infection between male and females was not statistically different (1.98 per 1000 women and 2.96 per 1000 men). Exposure to COVID-19 may not establish long-term protective immunity to all patients and may predispose them to re-infection. This fact can be reminded that the use of masks, social distancing and other preventive measures are very important in recovered patients and should be emphasised especially in health care personnel who are more exposed to the virus.

Indexed as

COVID-19AdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansIranMaleMiddle AgedReinfectionSARS-CoV-2COVID-19incidencere-infectionSARS-COV

Identifiers

PMID33866988
PMCPMC8267335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.